e-Article
Prostate-specific antigen doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer
Document Type
article
Author
Taketo Kawai; Satoru Taguchi; Keina Nozaki; Naoki Kimura; Takahiro Oshina; Takuya Iwaki; Hotaka Matsui; Aya Niimi; Jun Kamei; Yoshiyuki Akiyama; Yuta Yamada; Yusuke Sato; Daisuke Yamada; Tomoyuki Kaneko; Subaru Sawayanagi; Hidetsugu Nakayama; Ryogo Minamimoto; Hideomi Yamashita; Hideyo Miyazaki; Tetsuya Fujimura; Tohru Nakagawa; Haruki Kume
Source
Prostate International, Vol 11, Iss 4, Pp 239-246 (2023)
Subject
Language
English
ISSN
2287-8882
Abstract
Background: In recent years, site-directed therapies (SDTs) targeting progressive lesions in patients with oligometastatic prostate cancer have attracted attention. However, whether they effectively treat oligoprogressive castration-resistant prostate cancer (CRPC) remains unclear. Here, we investigated the efficacy of SDT in patients with oligoprogressive CRPC and identified prognostic factors. Methods: We reviewed 59 patients with oligoprogressive CRPC who underwent SDT targeting prostate or metastatic lesions between April 2014 and March 2022. We evaluated the associations between several pretreatment clinical variables and treatment procedures and a >50% prostate-specific antigen (PSA) response, progression-free survival (PFS), and time to next treatment (TTNT). Results: A PSA response of >50% was observed in 66% of patients. The median PFS and TTNT were 8.3 months and 9.9 months, respectively. Patients with PSA doubling time ≥6 months showed a higher >50% PSA response rate (87% vs. 45%; P 50% PSA response, favorable PFS, and TTNT (P = 0.037, 0.025, and 0.017, respectively). Conclusion: PSA doubling time of ≥6 months may be a key indicator of the favorable efficacy of SDT for oligoprogressive CRPC.